Total
0
Shares
Acrux (ASX:ACR) - Managing Director & CEO, Michael Kotsanis
Managing Director & CEO, Michael Kotsanis
Source: Acrux
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Acrux (ACR) has wrapped up a share purchase plan that was more than seven times oversubscribed after receiving approximately $15.1 million in applications
  • The placement has since been scaled back to roughly $9.9 million, but still marks a significant increase on the $2 million it was initially seeking
  • ACR says funds will go towards developing a “pipeline” of products, working capital and covering fundraising costs
  • Combined with the company’s placement from December last year, Acrux is set to net $17.7 million all up
  • Acrux shares are up a solid 8.57 per cent following the news, closing the session at 19 cents flat

Acrux (ACR) has wrapped up a share purchase plan (SPP) that was more than seven times oversubscribed after receiving $15.1 million in applications.

The drug development company had initially sought $2 million under the SPP but has decided it will increase the plan to $9.9 million, given the interest from investors.

The company says proceeds from the offer will be used to develop and commercialise “the current and future pipeline of products”, provide working capital and cover the costs of the placement and SPP.

Due to the oversubscription, Acrux has scaled back valid applications, mostly on a pro-rata basis, based on the stake of eligible shareholders, with excess cash set to be refunded.

In total, 63,298,095 ordinary shares are set to be issued at $0.157 each,
per share on Wednesday February 3 with quotation of the SPP shares expected on Thursday February 4, 2021.

It comes on the back of the company’s $7.8 million placement to new and existing institutional, sophisticated and professional investors in December last year.

Following the completion of the placement and SPP, Acrux says it has raised gross proceeds of $17.7 million.

Acrux Chairman Ross Dobinson said he is pleased with the response from the market.

“The directors of Acrux Limited would like to thank our shareholders for their continued support. Acrux is at an exciting stage of its development and looks forward to the next phase of commercialising its products,” he concluded.

Acrux shares are up a solid 8.57 per cent following the news, closing the session at 19 cents flat.

ACR by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.